Charles River Hones Biologics Business, Adding Lab Space
"The high volume of biologics and biosimilars in development has led to a rapid increase in demand for our services," said Greg Beattie, Charles River's head of global biologics testing solutions, in a statement. "The continued expansion of our biologics service portfolio and additional capacity will further enhance our ability to support clients' development efforts from discovery through clinical phases and commercial manufacturing."
Even though small molecule drugs still make up the bulk of industry sales, drug manufacturers are increasingly moving toward large molecule biologics, including biosimilars. These drugs require much longer timelines to manufacture and are significantly more difficult and costly to produce.